CY1121478T1 - Μεθοδοι καθαρισμου rna - Google Patents

Μεθοδοι καθαρισμου rna

Info

Publication number
CY1121478T1
CY1121478T1 CY20191100284T CY191100284T CY1121478T1 CY 1121478 T1 CY1121478 T1 CY 1121478T1 CY 20191100284 T CY20191100284 T CY 20191100284T CY 191100284 T CY191100284 T CY 191100284T CY 1121478 T1 CY1121478 T1 CY 1121478T1
Authority
CY
Cyprus
Prior art keywords
rna
methods
combination
purification methods
rna purification
Prior art date
Application number
CY20191100284T
Other languages
English (en)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of CY1121478T1 publication Critical patent/CY1121478T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D2015/3838—Ligand exchange chromatography, e.g. complexation chromatography, chelation chromatography, metal interaction chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Water Supply & Treatment (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Μέθοδοι για καθαρισμό RNA από δείγμα, που περιλαμβάνουν ένα ή περισσότερα στάδια διήθησης εφαπτομενικής ροής, χρωματογραφίας υδροξυαπατίτη, χρωματογραφίας σφαιριδίου πυρήνα χωρίς δέσμευση προϊόντος ή οποιωνδήποτε συνδυασμών αυτών. Αυτές οι τεχνικές είναι χρήσιμες ξεχωριστά, αλλά παρουσιάζουν πολύ υψηλή αποτελεσματικότητα όταν χρησιμοποιούνται σε συνδυασμό ή όταν πραγματοποιούνται σε συγκεκριμένες σειρές. Οι μέθοδοι μπορούν να καθαρίσουν RNA με ιδιαιτέρως αποτελεσματικό τρόπο χωρίς να διακυβεύεται υπερβολικά η δραστικότητα ή η σταθερότητα, ώστε να παρέχουν συνθέσεις στις οποίες RNA είναι ουσιαστικά καθαρισμένο από ανεπιθύμητες προσμίξεις. Επιπλέον, μπορούν να πραγματοποιηθούν χωρίς την ανάγκη για οργανικούς διαλύτες.
CY20191100284T 2013-03-15 2019-03-12 Μεθοδοι καθαρισμου rna CY1121478T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799705P 2013-03-15 2013-03-15
PCT/EP2014/055014 WO2014140211A1 (en) 2013-03-15 2014-03-13 Rna purification methods

Publications (1)

Publication Number Publication Date
CY1121478T1 true CY1121478T1 (el) 2020-05-29

Family

ID=50272650

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100284T CY1121478T1 (el) 2013-03-15 2019-03-12 Μεθοδοι καθαρισμου rna

Country Status (17)

Country Link
US (1) US11155572B2 (el)
EP (2) EP3521429B1 (el)
JP (1) JP6461830B2 (el)
CN (1) CN105283548A (el)
BR (1) BR112015023513A2 (el)
CA (1) CA2906281A1 (el)
CY (1) CY1121478T1 (el)
DK (1) DK2970948T3 (el)
ES (2) ES2923018T3 (el)
HR (1) HRP20190197T1 (el)
HU (1) HUE042072T2 (el)
LT (1) LT2970948T (el)
PL (1) PL2970948T3 (el)
PT (1) PT2970948T (el)
SI (1) SI2970948T1 (el)
TR (1) TR201903248T4 (el)
WO (1) WO2014140211A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
PT3134131T (pt) 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
BR112016024632A2 (pt) 2014-04-25 2018-01-30 Shire Human Genetic Therapies métodos de purificação de rna mensageiro
EP3294885B1 (en) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Method for producing rna
EP3744843A1 (en) 2015-05-29 2020-12-02 CureVac Real Estate GmbH A method for producing and purifying rna, comprising at least one step of tangential flow filtration
DK3332019T3 (da) 2015-08-07 2020-02-17 Curevac Ag Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
WO2017083286A1 (en) 2015-11-09 2017-05-18 University Of Notre Dame Particle size purification method and devices
IL260257B2 (en) 2015-12-28 2024-05-01 Novartis Ag Preparations and methods for the treatment of hemoglobinopathies
CA3031095A1 (en) * 2016-07-21 2018-01-25 Spark Therapeutics, Inc. Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby
WO2018041921A1 (en) 2016-08-31 2018-03-08 Curevac Ag Mixing device for the production of a liquid nucleic acid composition
CN109937253B (zh) 2016-09-14 2023-06-30 摩登纳特斯有限公司 高纯度rna组合物及其制备方法
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
DK3585891T3 (da) 2017-02-27 2021-11-22 Translate Bio Inc Fremgangsmåder til oprensning af messenger-rna
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US20200325527A1 (en) 2017-08-11 2020-10-15 Glaxosmithkline Biologicals Sa Rna identity method using rnase h digestion and size fractionating
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
EP3721221A1 (en) * 2017-12-07 2020-10-14 EMP Biotech GmbH System and method of applied radial technology chromatography
WO2020002598A1 (en) * 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
AU2019325702A1 (en) 2018-08-24 2021-02-25 Translate Bio, Inc. Methods for purification of messenger RNA
JP7419354B2 (ja) * 2018-10-24 2024-01-22 エフ． ホフマン－ラ ロシュ アーゲー オリゴヌクレオチドの精製プロセス
WO2020160087A1 (en) * 2019-01-29 2020-08-06 Flagship Pioneering Innovations V, Inc. Methods of separating long polynucleotides from a composition
EP3924487B1 (en) * 2019-02-11 2024-04-10 ethris GmbH Mrna purification by tangential flow filtration
US20220306678A1 (en) * 2019-06-20 2022-09-29 Arcturus Therapeutics, Inc. Improved in vitro transcription purification platform
JP2023506842A (ja) 2019-12-18 2023-02-20 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
US11576966B2 (en) 2020-02-04 2023-02-14 CureVac SE Coronavirus vaccine
CA3168716A1 (en) * 2020-02-21 2021-08-26 Biogen Ma Inc. Methods of preparing oligonucleotide compositions using ultrafiltration / diafiltration
JP2023528586A (ja) * 2020-05-12 2023-07-05 クランフィールド ユニヴァーシティー Ｒｎａを用いた治療薬の合成方法及び合成モジュール式装置
CN111812230A (zh) * 2020-06-24 2020-10-23 南京济群生物科技有限公司 一种半定量测定dna中rna含量的sec-hplc检测方法
CN116367903A (zh) * 2020-09-14 2023-06-30 恩奎斯特技术公司 生物制剂制造及下游纯化工艺技术
WO2022240960A1 (en) * 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
WO2022266389A1 (en) * 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
WO2023031858A1 (en) 2021-09-01 2023-03-09 Glaxosmithkline Biologicals Sa Plasmid dna purification methods
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
WO2024072904A2 (en) * 2022-09-28 2024-04-04 Modernatx, Inc. Purification of nucleotides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
US6011148A (en) 1996-08-01 2000-01-04 Megabios Corporation Methods for purifying nucleic acids
EP0853123A1 (de) 1997-01-10 1998-07-15 Roche Diagnostics GmbH Reinigung von DNA durch Cross-Flow-Filtration
WO1999040098A1 (de) 1998-02-04 1999-08-12 Merck Patent Gmbh Verfahren zur isolierung und aufreinigung von nucleinsäuren
WO2003031582A2 (en) * 2001-10-09 2003-04-17 Genentech, Inc. Novel acidic mammalian proteins and polynucleotides encoding the same
US8075780B2 (en) 2003-11-24 2011-12-13 Millipore Corporation Purification and concentration of synthetic biological molecules
DE602005012382D1 (de) 2004-05-18 2009-03-05 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
EP3449910A1 (en) 2010-07-06 2019-03-06 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
PT2590676T (pt) 2010-07-06 2016-11-04 Glaxosmithkline Biologicals Sa Partículas de transferência de tipo virião para moléculas de arn auto-replicante
US20130189757A1 (en) * 2010-07-16 2013-07-25 Valorisation-Recherche, Limited Partnership Affinity purification of rna under native conditions based on the lambda boxb/n peptide interaction
PL3981427T3 (pl) 2010-08-31 2022-09-19 Glaxosmithkline Biologicals S.A. Pegylowane liposomy do dostarczania rna kodującego immunogen
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
PT4043040T (pt) 2010-08-31 2023-03-24 Glaxosmithkline Biologicals Sa Lipossomas pequenos para entrega de arn que codifica um imunogénio
JP2014506873A (ja) 2010-12-10 2014-03-20 トンプソン トレイシー 分離方法のための組成物
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
SG10201605500TA (en) 2011-07-06 2016-08-30 Novartis Ag Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
DE112012005583B4 (de) * 2012-01-06 2023-05-17 Infinity Fuel Cell And Hydrogen Inc. Elektrochemische Zelle mit verbesserter Wasser- oder Gaswirtschaft
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA

Also Published As

Publication number Publication date
EP2970948B1 (en) 2018-12-26
JP6461830B2 (ja) 2019-01-30
DK2970948T3 (en) 2019-04-08
ES2720200T3 (es) 2019-07-18
PL2970948T3 (pl) 2019-06-28
HUE042072T2 (hu) 2019-06-28
SI2970948T1 (sl) 2019-04-30
EP2970948A1 (en) 2016-01-20
EP3521429A1 (en) 2019-08-07
US11155572B2 (en) 2021-10-26
TR201903248T4 (tr) 2019-03-21
ES2923018T3 (es) 2022-09-22
US20160024139A1 (en) 2016-01-28
CA2906281A1 (en) 2014-09-18
JP2016512212A (ja) 2016-04-25
LT2970948T (lt) 2019-03-25
CN105283548A (zh) 2016-01-27
US20210214388A1 (en) 2021-07-15
WO2014140211A1 (en) 2014-09-18
PT2970948T (pt) 2019-03-20
BR112015023513A2 (pt) 2017-07-18
HRP20190197T1 (hr) 2019-04-05
EP3521429B1 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
CY1121478T1 (el) Μεθοδοι καθαρισμου rna
DK4108769T3 (da) Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
CY1118442T1 (el) Μεθοδοι αγωγης δια της χρησεως εκλεκτικων αναστολεων bcl-2
CY1120556T1 (el) Δικυκλικα ετεροκυκλα ως αναστολεις fgfr
CU20170163A7 (es) Compuestos derivados de d-fenilalanina-n-sustituido con biciclos aromáticos, método de preparación de las mismas y composiciones farmacéuticas que los contienen
DK3585892T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3585891T3 (da) Fremgangsmåder til oprensning af messenger-rna
DK3467108T3 (da) Fremgangsmåder til oprensning af messenger-RNA
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
DK2992115T3 (da) Multipleksmærkning af molekyler ved stregkodning med sekventiel hybridisering
FR3014901B1 (fr) Procede de purification de virus ou vecteurs viraux enveloppes
DK3828277T3 (da) Sammensætninger, fremgangsmåder og apparatur til syntese af oligonukleotider
CY1120595T1 (el) Μεθοδος καθαρισμου cys-συνδεδεμενων συζευγματων αντισωματος-φαρμακου
BR112015004111A2 (pt) novos derivados bicíclicos
UA114087C2 (xx) Похідні піридину
EA201490299A1 (ru) Способ удаления примесей из конденсата топочного газа
BRPI0812222A2 (pt) Compostos ciclobutenodiona substituídos anti-inflamatórios.
UY35873A (es) ?composiciones y métodos para el control de virus en el ácaro varroa y las abejas?.
DK2598500T3 (da) Sammensætninger og fremgangsmåder til hæmning af jak-reaktionsvejen
EA201592184A1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные
CY1120679T1 (el) Παραγωγα βενζιμιδαζολης και φαρμακευτικες συνθεσεις εξ' αυτων για την αγωγη φλεγμονωδων διαταραχων
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
EA032920B1 (ru) Способы получения соединений бензохинолина
DOP2016000278A (es) Nuevos compuestos macrocíclicos
CY1121515T1 (el) Μεθοδοι και συνθεσεις για την επουλωση πληγων